Regeneron (REGN) Misses Q1 EPS by 15c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Regeneron Pharma (REGN) PT Raised to $400 at Barclays Following 1Q Report; 'Initial Strength of the Dupixent Launch'
May 5, 2017 2:46 PM EDTBarclays raised its price target on Regeneron Pharma (NASDAQ: REGN) to $400.00 (from $375.00) while maintaining a Equalweight rating, following the company's first quarter earnings report.
Analyst Geoff Meachem notes the company produced revenues above consensus, but missed on earnings per share print, as investors focus on the strong Dupixent launch.
... MoreRegeneron Pharma (REGN) PT Raised to $475 at Cowen
May 4, 2017 3:39 PM EDTCowen raised its price target on Regeneron Pharma (NASDAQ: REGN) to $475.00 (from $380.00) while maintaining a Market Perform rating following Q1 results.
Analyst Phil Nadeau is updating estimates to reflect Dupixent's fast start, Eylea's deceleration.
FY 2017 EPS goes from $12.25 to $1.25 and FY 2018 EPS goes from $14.90 to $13.20.
... More